GNMSF — GENMAB A/S
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1434265 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,155,000,000 | 1,071,000,000 | 407,000,000 | 303,000,000 | 12,515,000,000 | 1,503,000,000 | 6,558,000,000 |
| Mar 2026 | 896,000,000 | 831,000,000 | 225,000,000 | 53,000,000 | 12,376,000,000 | 1,521,000,000 | 6,694,000,000 |
| Dec 2025 | 1,058,000,000 | 977,000,000 | 243,000,000 | 31,000,000 | 12,873,000,000 | 1,715,000,000 | 7,026,000,000 |
| Sep 2025 | 1,022,000,000 | 964,000,000 | 459,000,000 | 401,000,000 | 7,021,000,000 | 1,761,000,000 | 1,270,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$902,000,000
Investing CF
$-5,609,000,000
Financing CF
$4,625,000,000
CapEx
$-30,000,000
Dividends Paid
—
Buybacks
$-526,000,000
EPS Diluted TTM
$9.30
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$4,421,000,000
Inventory
$18,000,000
Receivables
$1,280,000,000
ST Investments
$0
EBIT TTM
$1,175,000,000
Pretax Income TTM
$906,000,000
Interest Exp TTM
$269,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,131,000,064
EBITDA
$1,376,999,936
Free Cash Flow
$870,625,024
Enterprise Value
$23,419,727,872
Total Cash
$1,510,000,000
Total Debt
$5,272,999,936
Shares Out
61,490,254
Trailing EPS
$12.64
Book Value
$99.78
ROE
14.0%
ROA
8.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,720,000,000 | 1,250,000,000 | 963,000,000 | 12,873,000,000 | 7,026,000,000 | 5,847,000,000 | 1,186,000,000 |
| Dec 2024 | 3,121,000,000 | 1,015,000,000 | 1,133,000,000 | 6,414,000,000 | 1,277,000,000 | 5,137,000,000 | 1,126,000,000 |
| Dec 2023 | 2,390,000,000 | 772,000,000 | 631,000,000 | 5,232,000,000 | 545,000,000 | 4,687,000,000 | 1,071,000,000 |
| Dec 2022 | 2,087,681,170 | 901,999,165 | 784,697,534 | 4,334,978,914 | 408,324,818 | 3,926,654,097 | 563,047,827 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$13.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.04T | $1169.60 | — |
| JNJ | JOHNSON & JOHNSON | $618.09B | $256.48 | — |
| ABBV | AbbVie Inc. | $481.40B | $272.42 | — |
| MRK | Merck & Co., Inc. | $351.28B | $142.38 | — |
| NVS | NOVARTIS AG | $272.01B | $143.11 | — |
News headlines (Yahoo Finance, 1h cache)
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
2026-10-07 16:17 · Yahoo
Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?
2026-10-07 07:16 · Yahoo
AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%
2026-10-07 05:12 · Yahoo
Genmab’s Lymphoma Bet Delivers a 51% Knockout
2026-10-06 16:39 · Yahoo
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
2026-10-06 15:42 · Yahoo
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
2026-10-06 14:22 · Yahoo
Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk
2026-10-06 07:52 · Yahoo
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
2026-10-06 07:48 · Yahoo
European stocks rise 1% as French debt calms and ECB’s Lane tempers hawks
2026-10-06 07:38 · Yahoo
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge
2026-10-05 21:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.